Lantern Pharma is trading 11.23% lower at $0.52, with broad market weakness the likeliest explanation for the move.
- No new company-specific catalyst was identified for November 5, 2026; the latest company announcements surfaced in the search were from October.
- The provided market context shows major U.S. indexes lower and biotech ETF XBI down 5.19%.
- The registered offering is not a new event explaining this session’s decline.